Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595704 | 0.86 | L3MBTL1 (0.47) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL4054602 | 0.86 | L3MBTL1 (0.49) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL27572284 | 0.84 | L3MBTL1 (0.48) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL3571448 | 0.84 | PTPRC (0.57) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL3391035 | 0.81 | RELA (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL1568239 | 0.80 | RXRA (0.54) | L3MBTL1TDP1MAPTLMNAMEN1 | |
| SCHEMBL30357935 | 0.78 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL30013864 | 0.77 | SLC6A3 (0.48) | L3MBTL1CYP1A2CYP2C19NPSR1MAPT | |
| SCHEMBL2068454 | 0.77 | ALDH1A1 (0.54) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL29997747 | 0.76 | L3MBTL1 (0.47) | L3MBTL1TDP1NPSR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | disclosed |
| US-7754744-B2 | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | SSTR5, SSTR3, SSTR1 | L3MBTL1 4885/4885CYP1A2 397/4885CYP2D6 594/4885 |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | L3MBTL1 4832/4885CYP1A2 1032/4885CYP2D6 1134/4885 |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | SSTR5, SSTR3, SSTR1 | L3MBTL1 4885/4885CYP1A2 397/4885CYP2D6 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.